Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akin Akinc(Alnylam Pharmaceuticals (United States)), Daniel G. Anderson(Massachusetts Institute of Technology), Christina Gamba‐Vitalo(Alnylam Pharmaceuticals (United States)), Ingo Röhl(Roche Pharma AG (Germany)), Róbert Langer(Massachusetts Institute of Technology), K. N. Jayaprakash(Alnylam Pharmaceuticals (United States)), J. Robert Dorkin(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Forma Therapeutics (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Michael S. Goldberg(Einstein Medical Center Philadelphia), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Elizaveta S. Leshchiner(Massachusetts Institute of Technology), Victor Koteliansky(Centre National de la Recherche Scientifique), June Qin(Alnylam Pharmaceuticals (United States))
Cited by 350
Related Papers
Transdermal drug delivery
|Nature Biotechnology|2008|3.4k
Physical and mechanical properties of PLA, and their functions in widespread applications — A comprehensive review
|Advanced Drug Delivery Reviews|2016|3.2k
Knocking down barriers: advances in siRNA delivery
|Nature Reviews Drug Discovery|2009|3.1k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k